BioSpace News Archive

On Tuesday February 16, at 16.00 CET, IRRAS will host a conference call and an online presentation of its Q4 2020 interim report.

SyntheticMR AB and United Imaging announced that they have signed a global license agreement, through which United Imaging will market and sell SyntheticMR’s product to customers globally.

Method, based on analysis of EEG patterns of abnormal brain electrical activity, can rapidly diagnose and monitor brain vascular pathology such as Alzheimer’s disease, stroke, head injuries as well as psychiatric conditions

neoX Biotech, a next-generation biotech company specializing in computational design for novel drug research and development, recently announced that it had raised US$30 million in Series A funding.

Proceeds to advance clinical evaluation of lead candidate INT-1B3 and further preclinical drug candidates towards the clinic

Drug Farm, a China- and US-based biotechnology company utilizing genetics and AI technologies to discover and develop innovative, immune-modulating therapies, has completed financing totaling $56 million USD.

InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by carotid artery disease, announced the appointment of Chris Metzger, M.D., system chair of clinical research at Ballad Health System in Eastern Tennessee as the principal investigator for its planned FDA registration trial for CGuard EPS.

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced the publication of a study in the journal Nature Medicine that used NanoString’s GeoMx® Digital Spatial Profiler and the new Whole Transcriptome Atlas to profile sarcoma tissue.

Centene Corporation announced its financial results for the fourth quarter and year ended December 31, 2020, reporting diluted earnings per share of $ and $3.12, respectively, and Adjusted diluted EPS of $0.46 and $5.00, respectively.

– Oral KVD900 Primary Endpoint Shows Only 15% Use of Rescue Medication in Patients with Hereditary Angioedema (HAE) – – KVD900 Generally Safe and Well-Tolerated – – Conference Call to Discuss Trial Results Today at 8:30 a.m. ET –